A SINGLE-CENTER OBSERVATIONAL STUDY OF CLINICAL OUTCOMES FOLLOWING TREATMENT OF LEIOMYOMA WITH COMBINATION THERAPY UTILIZING GNRH ANALOGS AND TRANSCERVICAL FIBROID ABLATION

Brief description of study

This is a prospective cohort study of patients who will receive TFA following medical therapy for fibroid care between 1/2023 and 1/2024 at our institution. Clinical variables of interest will be collected by chart review by the study team and will include characteristics of fibroids including diameter, location and volume, volume of uterus, medical management prior to TFA, need for surgical reintervention within 6-12 months following TFA due to heavy menstrual bleeding, and ultrasound and lab data prior to TFA and at 3, 6 and 12 months post procedure. Additional quality of life data collected by surveys will be summarized at all specified time points.


Clinical Study Identifier: s22-01365
Principal Investigator: Taraneh Shirazian.
Other Investigator: Alexandra Rebecca Pass.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.